This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

J&J Second-Quarter Profit Tops Estimates

Stocks in this article: JNJ

(Update: Adds insight into falling revenues, prior J&J announcements, and adds stock price.)

Its profit may have dipped because of slower sales this quarter, and currency exchanges didn't help, but Johnson & Johnson (JNJ) still beat analysts' estimates.

On Tuesday, Johnson & Johnson said it earned $3.21 billion, or $1.15 a share, in the quarter on sales of $15.24 billion, which were down 7.4% from the year-earlier period.

The company earned $3.33 billion, or $1.17 a share, in the year-earlier second quarter. The second quarter 2008 total also included a one-time $40 million R&D charge.

Analysts surveyed by Thomson Reuters had expected the New Jersey-based health industry bellwether to post earnings of $1.11 a share on revenue of $15.02 billion this quarter.

Revenue slowed thanks largely to a drop in prescription drug sales and increasing competition from generics. The giant healthcare conglomerate, known for making a diverse line of products, including Band-Aids and Listerine, said worldwide pharmaceutical sales fell 13.3% compared to the year-ago quarter.

Though worldwide consumer sales also dropped, the company pointed to stronger sales for items like Listerine, along with an uptick in skin care lines Neutrogena and Aveeno, as key product-growth drivers in the quarter. The company also slashed marketing and R&D costs by 12.9% and 13.6%, respectively, against the year-ago quarter.

Johnson & Johnson also confirmed its 2009 guidance, saying that earnings would land between $4.45 and $4.55 a share for the year after excluding certain items.

Last week, Johnson & Johnson completed its near $1 billion acquisition of Cougar Technology. Before that, Johnson & Johnson entered into an agreement to buy Elan's (ELN) stake in the Alzheimer drug market.

Shares of Johnson & Johnson were up 0.7%, or 43 cents, at $58.15 just after the opening bell.

Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,761.51 -16.64 -0.09%
S&P 500 2,064.33 +3.10 0.15%
NASDAQ 4,743.3640 -5.0320 -0.11%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs